Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 4/20 | 0.31 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5051893 | 0.89 | HDAC6 (0.38) | HDAC6HDAC1HDAC2CA14DGAT1 | |
| SCHEMBL30772730 | 0.87 | CA14 (0.39) | HDAC6HDAC1HDAC2CA14DGAT1 | |
| SCHEMBL30324896 | 0.85 | HDAC6 (0.38) | HDAC6HDAC1HDAC2CA14CTSK | |
| SCHEMBL13109092 | 0.85 | HDAC6 (0.38) | HDAC6HDAC1HDAC2CA14CTSK | |
| SCHEMBL2526136 | 0.82 | HDAC6 (0.39) | HDAC6HDAC1HDAC2CA14DGAT1 | |
| SCHEMBL380577 | 0.82 | HDAC6 (0.39) | HDAC6HDAC1HDAC2CA14CA12 | |
| SCHEMBL24714957 | 0.79 | CA14 (0.39) | HDAC6HDAC1HDAC2CA14CA12 | |
| SCHEMBL30020941 | 0.79 | HDAC6 (0.37) | HDAC6HDAC1HDAC2CA14CA12 | |
| SCHEMBL4693101 | 0.79 | HDAC6 (0.39) | HDAC6HDAC1HDAC2CA14DGAT1 | |
| SCHEMBL12326931 | 0.78 | CA14 (0.41) | HDAC6HDAC1HDAC2CA14CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109698-A1 | MALT-1 MODULATORS | EXSCIENTIA AI LIMITED (GB) | 2026-04-23 | — | — | US | disclosed |
| US-20250051327-A1 | MALT-1 MODULATORS | RECURSION PHARMACEUTICALS, INC. | 2025-02-13 | — | — | US | disclosed |
| EP-4247492-A1 | MALT-1 MODULATORS | Exscientia Al Limited (GB) | 2023-09-27 | — | — | EP | disclosed |
| WO-2022106857-A1 | MALT-1 MODULATORS | Exscientia Limited (GB) | 2022-05-27 | — | — | WO | disclosed |
| US-9079877-B2 | Process for preparing chiral compounds | PFIZER INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-9079877-B2 | Process for preparing chiral compounds | PFIZER INC. (US) | 2015-07-14 | — | — | US | disclosed |
| EP-2532660-B1 | Process for preparing chiral compounds | PFIZER PROD INC (US) | 2014-09-10 | — | — | EP | disclosed |
| US-20140187794-A1 | Process for Preparing Chiral Compounds | PFIZER INC. (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140187794-A1 | Process for Preparing Chiral Compounds | PFIZER INC. (US) | 2014-07-03 | — | — | US | disclosed |
| US-8642783-B2 | Process for preparing chiral compounds | PFIZER INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642783-B2 | Process for preparing chiral compounds | PFIZER INC. (US) | 2014-02-04 | — | — | US | disclosed |
| EP-2532660-A1 | Synthetic intermediates prepared using a 2-deoxyribose-5-phosphate aldolase (DERA) chemoenzymatic process | Pfizer Products Inc. (US) | 2012-12-12 | — | — | EP | disclosed |
| US-20110118476-A1 | Process for Preparing Chiral Compounds | PFIZER INC. | 2011-05-19 | — | — | US | disclosed |
| US-20110118476-A1 | Process for Preparing Chiral Compounds | PFIZER INC. | 2011-05-19 | — | — | US | disclosed |
| US-20100298392-A1 | Isoindoline Derivatives For The Treatment Of Arrhythmias | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | US | disclosed |
| WO-2009019561-A2 | PROCESS FOR PREPARING CHIRAL COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2009-02-12 | — | — | WO | disclosed |
| US-5856326-A | ANTITUMOR, ANTICANCER AGENTS | MERCK & CO., INC. (US) | 1999-01-05 | — | — | US | disclosed |
| WO-1996030343-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1996-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140187794-A1 | Process for Preparing Chiral Compounds | DERA, ALDOA, DPYD | HDAC6 4618/4885HDAC1 4526/4885HDAC2 3766/4885 |
| US-20110118476-A1 | Process for Preparing Chiral Compounds | DERA, ALDOA, DPYD | HDAC6 4618/4885HDAC1 4526/4885HDAC2 3766/4885 |
| US-20250051327-A1 | MALT-1 MODULATORS | MALT1, BCL6, BCL9 | HDAC6 675/4885HDAC1 348/4885HDAC2 741/4885 |
| US-20100298392-A1 | Isoindoline Derivatives For The Treatment Of Arrhythmias | KCNH1, KCNH2, KCNQ2 | HDAC6 3753/4885HDAC1 2154/4885HDAC2 1785/4885 |
| US-20260109698-A1 | MALT-1 MODULATORS | MALT1, BCL6, BCL3 | HDAC6 2099/4885HDAC1 967/4885HDAC2 2184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.